Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders re-elected J. Martin Carroll and Sheldon L. Koenig as Class I directors through the 2029 annual meeting.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Shareholders re-elected J. Martin Carroll and Sheldon L. Koenig as Class I directors through the 2029 annual meeting
- Executive compensation received advisory approval, with 95,650,226 votes for and 34,866,033 against
- Ernst & Young’s appointment ratified for fiscal 2026, with 167,083,447 votes for
- 2022 Plan share authorization increased by 7,000,000 shares, creating additional potential equity dilution
- 177,208,856 shares represented at the meeting, establishing quorum from 257,404,876 shares outstanding
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Shareholders approved an amendment to Esperion’s 2022 Stock Option and Incentive Plan
- Amendment details appear in the April 16, 2026 Definitive Proxy Statement
- Expanded equity-plan capacity could support employee retention and incentive compensation
- Full Plan Amendment filed as Exhibit 10.1 for terms affecting potential dilution and awards
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.